Lessons learned from biosimilar epoetins and insulins
Authors:
- 1 March 2010
- journal article
- Published by SAGE Publications in British Journal of Diabetes
- Vol. 10 (2) , 90-97
Abstract
Patients with diabetes and renal failure may already be receiving biosimilar epoetin and may receive biosimilar insulin in the near future. Because these biosimilar pharmaceuticals (or follow-on biologics) are complex protein molecules manufactured in lengthy and inherently variable processes involving living organisms, they have the potential to induce an immunogenic, rather than a therapeutic, response. This response is dependent as much on the method of manufacture and formulation, as on the protein itself. Apparently small and innocuous differences in manufacture and formulation can lead to unforeseen clinical consequences. This article discusses two case studies illustrating this principle, that of three insulin formulations which were physicochemically similar to comparator insulins, but with pharmacokinetic and pharmacodynamic profiles sufficiently different to have potentially serious clinical consequences and that of Eprex, for which an apparently minor change in one formulation caused an upsurge of cases of pure red cell aplasia which resulted in fatalities or complete transfusion dependence. Comprehensive and rigorous testing and long-term pharmacovigilance programmes are essential to detect and forestall such consequences.Keywords
This publication has 24 references indexed in Scilit:
- European regulatory guidelines for biosimilarsNephrology Dialysis Transplantation, 2006
- Comparative testing and pharmacovigilance of biosimilarsNephrology Dialysis Transplantation, 2006
- The protein science of biosimilarsNephrology Dialysis Transplantation, 2006
- Biosimilars: How similar or dissimilar are they? (Review Article)Nephrology, 2006
- Therapeutic insulins and their large-scale manufactureApplied Microbiology and Biotechnology, 2004
- Epoetin AlfaArchives of internal medicine (1960), 2004
- Epoetin BetaDrugs, 2004
- ‘Biogenerics’: the off-patent biotech productsTrends in Pharmacological Sciences, 2002
- Present and future strategies in the treatment of renal anaemiaNephrology Dialysis Transplantation, 2001
- Some Chemical Properties of Human Erythropoietin*Endocrinology, 1985